Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Polly D. Gregor"'
Autor:
Polly D. Gregor, José A. Guevara-Patiño, Taha Merghoub, Francesca Orlandi, Alan N. Houghton, Jedd D. Wolchok
Publikováno v:
Vaccine. 29:3646-3654
HER2/neu is an oncogene amplified and over-expressed in 20-30% of breast adenocarcinomas. Treatment with the humanized monoclonal antibody trastuzumab has shown efficacy in combination with cytotoxic agents, although resistance occurs over time. Nove
Autor:
José A. Guevara-Patiño, Manuel E. Engelhorn, P. O. Livingston, Polly D. Gregor, Cailan Liu, Colin S.B. Houghton, Da Song, Jedd D. Wolchok, Alan N. Houghton, Francesca Orlandi, James McCracken
Publikováno v:
Vaccine. 25:5330-5342
One strategy to generate T-cell responses to tumors is to alter subdominant epitopes through substitution of amino acids that are optimal anchors for specific MHC molecules, termed heteroclitic epitopes. This approach is manually error-prone and time
Autor:
J. Liao, Isabelle Riviere, M. A. Camps-Palau, Polly D. Gregor, Michel Sadelain, Ann E. Hohenhaus, Miguel-Angel Perales, Joanne McKnight, Jedd D. Wolchok, C. Leung, Philip J. Bergman, Alan N. Houghton, Diane M Craft, Nicole F. Leibman
Publikováno v:
Vaccine. 24:4582-4585
Introduction Canine malignant melanoma (CMM) is an aggressive neoplasm treated with surgery and/or fractionated RT; however, metastatic disease is common and chemoresistant. Preclinical and clinical studies by our laboratory and others have shown tha
Autor:
Vandana Turaga, Polly D. Gregor, Jean Baptiste Latouche, Warren D. W. Heston, Michel Sadelain, Howard I. Scher, Jedd D. Wolchok, Alan N. Houghton, Dean J. Bacich
Publikováno v:
International Journal of Cancer. 116:415-421
Prostate-specific membrane antigen (PSMA) is a prototypical differentiation antigen expressed on normal and neoplastic prostate epithelial cells, and on the neovasculature of many solid tumors. Monoclonal antibodies specific for PSMA are in developme
Autor:
Fariborz Mortazavi, Warren D. W. Heston, James P. Allison, Polly D. Gregor, Alan N. Houghton, Miguel-Angel Perales, Michel Sadelain, Dean J. Bacich, Heidi Buchinshky, Jean Baptiste Latouche, Howard I. Scher, José A. Guevara-Patiño, Jedd D. Wolchok, Cristina R. Ferrone
Publikováno v:
Vaccine. 22:1700-1708
Xenogeneic DNA vaccination can elicit tumor immunity through T cell and antibody-dependent effector mechanisms. Blockade of CTLA-4 engagement with B7 expressed on APCs has been shown to enhance T cell-dependent immunity. We investigated whether CTLA-
Autor:
Govind Ragupathi, Natarajan Sathyan, Fusataka Koide, Maria Spassova, Polly D. Gregor, Celso A. Reis, Philip O. Livingston, Henrik Clausen, Samuel J. Danishefsky, Ella Kagan, William Bornmann
Publikováno v:
Cancer Immunology, Immunotherapy. 52:608-616
Previously using a series of monovalent vaccines, we demonstrated that the optimal method for inducing an antibody response against cancer cell-surface antigens is covalent conjugation of the antigens to keyhole limpet hemocyanin (KLH) and the use of
Publikováno v:
Seminars in Oncology. 30:659-666
Immunotherapy is currently being investigated as a treatment for patients with asymptomatic, recurrent prostate cancer manifested only by a rising prostate-specific antigen (PSA) level. Several different approaches to active immunization against anti
Autor:
Jason S. Gold, Nathalie E. Blachere, Polly D. Gregor, Miguel-Angel Perales, Manuel E. Engelhorn, Alan N. Houghton, Cristina R. Ferrone, Jedd D. Wolchok, Gabriele Noffz
Publikováno v:
Seminars in Cancer Biology. 12:63-71
Cancer poses a difficult problem for immunotherapy because it arises from the host's own tissues. Many of the target antigens are tissue-specific molecules shared by cancer cells and normal cells. Thus, these are weak antigens that do not typically e
Publikováno v:
The EMBO Journal. 16:7091-7104
The transcription factor TFII‐I has been shown to bind independently to two distinct promoter elements, a pyrimidine‐rich initiator (Inr) and a recognition site (E‐box) for upstream stimulatory factor 1 (USF1), and to stimulate USF1 binding to
Publikováno v:
Clinical genitourinary cancer. 10(2)
Patients with metastatic melanoma or castration-resistant metastatic prostate cancer have limited life expectancy. We report the case of a patient with metastatic melanoma who was free of disease progression for 18 years and whose prostate cancer, di